[Human recombinant erythropoietin in treatment of uremic anemia in children with continual ambulatory peritoneal dialysis].

Human recombinant erythropoietin has been administered to 6 children with uremic anaemia in the course of end stage renal disease, treated with CAPD. The drug has been injected subcutaneously in the dose of 2,000 U twice a week, until hematocrit and hemoglobin values equivalent to 30% and 9-10 g/dL have been achieved. A decrease in cytotoxic antibodies titre has been noted during a 6-month follow-up. No serious adverse reactions have been seen.